The global diabetic macular edema market is on a steady growth trajectory, with its value expected to rise from USD 4,120.9 million in 2024 to USD 4,642.9 million by 2034. This represents a modest Compound Annual Growth Rate (CAGR) of 1.20% over the next decade, driven by an increasing demand for effective treatment solutions for this serious diabetes-related complication.
Diabetic macular edema is a leading cause of vision impairment and blindness worldwide, with its prevalence escalating alongside the rising incidence of diabetes. As the global diabetic population continues to grow, so does the urgent need for effective management and treatment strategies for DME.
Recent advancements in medical technology have significantly enhanced the diagnosis and treatment of DME, offering renewed hope to millions affected by this condition. Innovations such as anti-VEGF (vascular endothelial growth factor) drugs, intravitreal injections, and corticosteroid therapies have revolutionized DME treatment. These state-of-the-art therapies not only provide more effective solutions but also offer less invasive options, thereby improving patient quality of life and significantly reducing the risk of vision loss.
Increased awareness of diabetic macular edema among healthcare professionals and patients is also playing a crucial role in the market’s growth. This heightened awareness is facilitating earlier detection and intervention, which are vital for effective management of the condition. The synergy of early diagnosis and the availability of advanced treatment modalities is driving the demand for DME therapies worldwide.
Looking ahead, the global diabetic population’s growth will continue to prioritize the need for innovative and effective treatment options for DME. The market’s steady expansion reflects ongoing advancements in medical technology and the healthcare community’s commitment to improving outcomes for those living with diabetic macular edema.
“The diabetic macular edema industry presents several opportunities for growth and innovation,” said an FMI Analyst. “One key opportunity lies in the development of novel therapies and treatment modalities. Advances in biotechnology, gene therapy, and regenerative medicine hold promise for revolutionizing DME treatment by targeting underlying disease mechanisms and providing more durable and long-lasting outcomes for patients.”
Key Takeaways from the Market Study:
- The United Kingdom anticipates moderate momentum in the diabetic macular edema sector, with a CAGR of 1.1% from 2024 to 2034.
- Germany is expected to experience tempered growth in the diabetic macular edema market, with a projected CAGR of 3.2% from 2024 to 2034.
- Intravitreal injections account for a leading share of 94.8% in the form segment in 2024.
- India foresees sluggish rise in the diabetic macular edema industry, with a CAGR of 1.4% from 2024 to 2034.
- China is poised to witness stable expansion in the diabetic macular edema sector, with a projected CAGR of 4.3% from 2024 to 2034.
- Anti-VEGF drugs hold a dominant share of 95.5% in the drug type segment in 2024.
Explore the Growing Demand for Diabetic Macular Edema: Get All the Insights in Our Comprehensive Report!
Competition Outlook of the Diabetic Macular Edema Market:
The diabetic macular edema market presents a robust competition and ongoing advancements in treatment modalities. With an increasing prevalence of diabetes worldwide, the demand for effective DME therapies continues to rise, fostering a competitive environment among pharmaceutical companies and biotech firms.
Key players in the diabetic macular edema market are actively engaged in research and development endeavors to introduce innovative drugs and therapies, aiming to address the unmet medical needs of patients. The market witnesses intense competition in the development of anti-VEGF drugs, corticosteroid therapies, and other off-label drugs targeting DME. Additionally, advancements in drug delivery systems such as intravitreal injections and implants further intensify competition, as companies strive to enhance treatment efficacy and patient compliance.
Strategic collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare organizations are shaping the market. These collaborations facilitate the exchange of scientific knowledge, clinical data, and resources, accelerating the development and commercialization of novel diabetic macular edema treatments. As the DME market continues to evolve, stakeholders must remain vigilant in navigating regulatory challenges, market dynamics, and emerging therapeutic trends to maintain a competitive edge and meet the evolving needs of patients.
Recent Developments:
- Novartis AG, headquartered in Switzerland, advances diabetic macular edema (DME) therapy as the FDA and EMA approve applications for BEOVU (brolucizumab-dbll), following favorable Phase III KESTREL trial findings.
- Bayer AG, located in Germany, has received FDA clearance for Eylea, an aflibercept solution for diabetic macular edema therapy, expanding its portfolio for ocular health.
- Allergan Plc., located in Ireland, has partnered with the International Diabetes Federation to develop a global strategy for DME screening, diagnosis, and therapy.
- Hoffmann-La Roche Ltd., located in Switzerland, has received FDA clearance for Vabysmo (faricimab-svoa) in DME therapy, citing good results from phase III trials on Vabysmo for retinal vein occlusion.
Leading Companies in the Diabetic Macular Edema Industry:
- Novartis AG
- Bayer AG
- Allergan Plc.
- F. Hoffmann-La Roche Ltd.
- Alimera Sciences Inc.
- Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
- KalVista Pharmaceuticals
- Genentech
- Oxurion (fka ThromboGenics)
- Ocugen, Inc
- Regeneron Pharmaceuticals, Inc.
- Clearside Biomedical
- Daiichi Sankyo
- Arctic Vision
- Chugai Pharmaceutical Co., Ltd.
Key Segments of Market Report:
By Drug Type:
Segmentation by drug includes anti-VEGF medications such as Ranibizumab (Lucentis) and Aflibercept (Eylea), as well as corticosteroid therapies like Dexamethasone (Ozurdex) and Fluocinolone Acetonide (Iluvien), alongside other off-label drugs.
By Form:
Classification by form distinguishes between intravitreal injections and intravitreal implants.
By Distribution Channel:
Regarding distribution channels, patients may access treatments through hospitals, specialty clinics, or mail order pharmacies.
By Region:
Geographical segmentation spans across regions including North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa (MEA).
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
